Novonesis (Novozymes) B (OTCPK:NVZMY)
$ 62.43 -0.16 (-0.26%) Market Cap: 28.99 Bil Enterprise Value: 30.86 Bil PE Ratio: 39.64 PB Ratio: 2.43 GF Score: 97/100

Novozymes A/S to Discuss the Continuation of Partnership with Bayer AG and with Two New Partners, Univar Solutions and UPL Ltd Call Transcript

Apr 05, 2019 / 06:00AM GMT
Release Date Price: $47.4 (+3.65%)
Operator

Welcome to the Novozymes conference call on the future setup of the Novozymes BioAg business. I will now hand it over to the 2 presenters from Novozymes. Please go ahead.

Tina SejersgÃ;rd FanÃ;Novozymes A;S;EVP of Agriculture;Bioenergy

¥¸,/-&

Good morning, everyone, and thank you for joining the call. Today, we will present the future setup of our BioAg business. My name is Tina Sejersgård Fanø, and I'm the Executive Vice President for the Agriculture and Bioenergy business. I'm joined here today by our CFO, Prisca Havranek-Kosicek, and Investor Relations. The presentation should take around 10 to 15 minutes. And after that, we'll answer your questions.

We are very happy to announce the outcome of the negotiations we have had with Bayer and other parties over the last quarters. But before getting into the details of that, I would like to remind you of the importance of our BioAg business and the reason for forming The BioAg Alliance with Monsanto 5 years ago.

During

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot